AtaiBeckley Inc.
BPL-003 · Mebufotenin Benzoate (5-MeO-DMT) Nasal Spray · Treatment-Resistant Depression
Company Overview
AtaiBeckley Inc. (formed November 2025 from the merger of Atai Life Sciences and Beckley Psytech; redomiciled from Netherlands to Delaware December 30, 2025) is a biopharmaceutical company advancing psychedelic-based therapeutics. Their lead asset BPL-003, a mebufotenin benzoate (5-MeO-DMT) nasal spray acquired from Beckley Psytech, completed Phase 2b with transformative results: 57.5% remission vs active comparator (0.3mg sub-perceptual dose) (p<0.0001) for treatment-resistant depression. The company is Phase 3-ready for TRD. Additional pipeline assets include VLS-01 (DMT buccal film, Phase 2) and EMP-01 (oral R-MDMA, Phase 2a, U.S. patent granted December 2025 with exclusivity through 2043). Cash runway extends into 2029.
Pipeline
| Drug / Compound | Stage | Indication |
|---|---|---|
BPL-003 Mebufotenin benzoate nasal spray (5-MeO-DMT) | Phase 2b Complete | Treatment-Resistant Depression |
VLS-01 DMT buccal film | Phase 2 | Major Depressive Disorder |
EMP-01 Oral R-MDMA | Phase 2a | Major Depressive Disorder |
Key Financials
- Cash Position
- Runway into 2029
- Burn Rate
- ~$25-30M/quarter
- Last Reported
- Q3 2025
Financial data is approximate. Always verify with official SEC filings.
Upcoming Catalysts
- Q1 2026EMP-01 (oral R-MDMA) Phase 2a topline data readoutClinical
- Q2 2026Phase 3 initiation for BPL-003 in Treatment-Resistant DepressionClinical
- H2 2026VLS-01 (DMT buccal film) Phase 2 readoutClinical
Recent News
- 2025-12EMP-01 U.S. patent granted December 2025 — exclusivity through 2043
- 2025-12AtaiBeckley redomiciled from Netherlands to Delaware, effective December 30, 2025
- 2025-11Atai Life Sciences and Beckley Psytech merge to form AtaiBeckley Inc.; BPL-003 Phase 2b results lead pipeline
- 2025-07Beckley Psytech BPL-003 Phase 2b: 57.5% remission vs active comparator (0.3mg sub-perceptual dose) in treatment-resistant depression
News items are manually curated from public company press releases.
External Links
Looking for psychedelic therapy?
Browse our directory of 700+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.
Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-02-25. Always consult official company filings and a qualified financial advisor before making investment decisions.